Table S5. Overall summary of previous and current studies comparing the effect of *SLCO1B1* genotype on drug levels and its effect by OATP1B1 inhibition.

Study	**Victim (OATP1B1 substrate)**	**Perpetrator (OATP1B1 inhibitor)**	**Average fold increased of AUC (comparing c.521CC and c.521TT)**	**Average fold increased of AUC by perpetrator (range for the different genotype group, TT, TC, CC)**	**Overall impact of *SLCO1B1* c.521T>C on OATP1B1 mediated interactions**
Kalliokoski et al. 2008[1]	Repaglinide (0.25 mg)	Gemfibrozil (1200 mg)	1.7 fold increase	7.3-8.2 fold	Fold increased slightly reduced in subjects with c.521T>C
He et al. 2009[2]	Atorvastatin (40 mg)	Rifampicin (600 mg)	2.2 fold	4.6-8.6 fold	Fold increased reduced in subjects with c.521T>C
This study	Pravastatin (40 mg)	Cyclosporin	1.9 fold increase	3.1–5.0 fold increase	Fold increased reduced in subjects with c.521T>C
	HDA	Cyclosporin	2.6 fold increase	1.2–2.0 fold increase	Fold increased reduced in subjects with c.521T>C and no increased in subjects with c.521CC
	TDA	Cyclosporin	4 fold increase	0.9–2.2 fold increase	Fold increased reduced in subjects with c.521T>C and no increased in subjects with c.521CC
	CP-I	Cyclosporin	2.6 fold increase	1.5–1.7 fold increase	Fold increased slightly reduced in subjects with c.521CC
	CP-III	Cyclosporin	1.4 fold increase	1.2–1.3 fold increase	Fold increased slightly reduced in subjects with c.521CC

References

1. Kalliokoski, A., Backman, J.T., Kurkinen, K.J., Neuvonen, P.J. & Niemi, M. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. *Clin Pharmacol Ther* **84**, 488-96 (2008).
2. He, Y.J. et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. *Clin Chim Acta* **405**, 49-52 (2009).